Africa: Rwanda Launches Africa's First Trial of Long-Acting Malaria Prevention Injection

Rwanda has initiated Africa's first clinical trial for a long-acting injectable drug designed to prevent malaria. This experimental treatment aims to provide extended protection, potentially offering a new tool against the disease amidst rising drug resistance and climate change.
Why it matters
Innovative medical interventions are essential for addressing the high global burden of malaria, particularly in Africa where the majority of cases occur.
Nairobi - Rwanda has launched Africa's first clinical trial of a long-acting injectable drug for malaria prevention, marking a potential shift in how the disease is prevented as drug resistance and climate change threaten progress against the mosquito-borne illness.
The Phase 1b trial, launched by Medicines for Malaria Venture (MMV) in partnership with Rwandan health research organisation Rinda Ubuzima, will assess the safety and tolerability of MMV371, an experimental drug designed to provide extended protection against malaria through a single injection.
The injectable could potentially protect recipients for an entire malaria season, reducing the need for frequent preventive medication if its safety and effectiveness are established.
The trial marks the first Phase 1 study of a malaria-prevention long-acting injectable to be conducted in Africa and will involve adults and adolescents in Rwanda.
Keep up with the latest headlines on WhatsApp | LinkedIn
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in